Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers

被引:80
作者
Albers, P [1 ]
Ganz, A [1 ]
Hannig, E [1 ]
Miersch, MDE [1 ]
Müller, SC [1 ]
机构
[1] Univ Bonn, Dept Urol, D-5300 Bonn, Germany
关键词
testis; germinoma; salvage therapy; neoplasm; residual; tumor markers; biological;
D O I
10.1016/S0022-5347(05)67365-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated the prognostic criteria for salvage surgery in patients with persistent marker elevation after chemotherapy for metastatic germ cell tumors. Materials and Methods: Of 125 men who underwent post-chemotherapeutic resection of residual tumors 30 had persistent marker elevation at surgery. This group was subdivided into 17 patients with no evidence of disease, 7 dead of disease and 6 others. Outcome analysis was performed in the subgroups with regard to preoperative and postoperative parameters. Mean followup was 120.3 months (range 1 to 228) after surgery. Results: Of the 30 patients 17 (57%) with persistently elevated tumor markers after chemotherapy were long-term survivors after salvage surgery. Overall persistent viable cancer and teratomatous elements were identified in 64% and 11% of cases, respectively. Significantly more patients died of disease who had a poor prognosis according to International Germ Cell Cancer Collaborative Group guidelines. Embryonal carcinoma was the predominant initial histology in this group and residual disease was more often located at various sites, for example the viscera, with a lower chance of complete surgical resection. Marker status before surgery, and chemotherapeutic pretreatment and postoperative histological findings did not differ significantly in patients with no evidence of disease and those dead of disease. Conclusions: Salvage surgery results in long-term success in greater than 50% of patients. Complete resection is the most important single parameter for a favorable outcome. Even patients with visceral metastasis benefit from surgery. Our data do not justify omitting surgery in certain subgroups.
引用
收藏
页码:381 / 384
页数:4
相关论文
共 14 条
  • [1] LATE RELAPSE OF TESTICULAR CANCER
    BANIEL, J
    FOSTER, RS
    GONIN, R
    MESSEMER, JE
    DONOHUE, JP
    EINHORN, LH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) : 1170 - 1176
  • [2] Cremerius U, 1998, J NUCL MED, V39, P815
  • [3] SURGICAL RESECTION IN PATIENTS WITH NONSEMINOMATOUS GERM-CELL TUMOR WHO FAIL TO NORMALIZE SERUM TUMOR-MARKERS AFTER CHEMOTHERAPY
    EASTHAM, JA
    WILSON, TG
    RUSSELL, C
    AHLERING, TE
    SKINNER, DG
    [J]. UROLOGY, 1994, 43 (01) : 74 - 80
  • [4] Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy?
    Foster, RS
    Donohue, JP
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 1998, 25 (03) : 479 - +
  • [5] OUTCOME ANALYSIS FOR PATIENTS WITH PERSISTENT NONTERATOMATOUS GERM-CELL TUMOR IN POSTCHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTIONS
    FOX, EP
    WEATHERS, TD
    WILLIAMS, SD
    LOEHRER, PJ
    ULBRIGHT, TM
    DONOHUE, JP
    EINHORN, LH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) : 1294 - 1299
  • [6] Kisbenedek L., 1995, International Urology and Nephrology, V27, P325, DOI 10.1007/BF02564770
  • [7] Mead GM, 1997, J CLIN ONCOL, V15, P594
  • [8] SURGICAL SALVAGE OF CHEMOREFRACTORY GERM-CELL TUMORS
    MURPHY, BR
    BREEDEN, ES
    DONOHUE, JP
    MESSEMER, J
    WALSH, W
    ROTH, BJ
    EINHORN, LH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) : 324 - 329
  • [9] Sheinfeld J, 1998, SEMIN ONCOL, V25, P203
  • [10] Germ cell tumor: Differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling
    Sugawara, Y
    Zasadny, KR
    Grossman, HB
    Francis, IR
    Clarke, MF
    Wahl, RL
    [J]. RADIOLOGY, 1999, 211 (01) : 249 - 256